DeuteRx Celebrates Women's History Month with Over a Decade of Pioneering Leadership in Drug Discovery

Chair, President, and CEO Sheila DeWitt, PhD, shares reflections and outlook on 15 Years of Drug Discovery and Four Landmark M&A Transactions

Mar. 31, 2026 at 6:45pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a collection of polished, geometric objects representing the key elements of pharmaceutical innovation and entrepreneurship, including a glass beaker, a molecular model, a metal syringe, and a bronze trophy, arranged elegantly on a clean, white seamless background with dramatic studio lighting and deep shadows.Symbolic objects representing the pioneering pharmaceutical innovations and entrepreneurial success of DeuteRx CEO Dr. Sheila DeWitt.Boston Today

DeuteRx today issues a State of the Union update on the scientific contributions and executive leadership of Sheila DeWitt, PhD, Chair, President, and CEO, whose work has advanced and redefined pharmaceutical innovation for more than three decades. Dr. DeWitt invented Deuterium-Enabled Chiral Switching (DECS) in 2010, a novel strategy to stabilize interconverting stereoisomers in racemic drugs to facilitate development of the preferred stereoisomers and create improved therapeutics.

Why it matters

DeuteRx celebrates women and women-led companies driving leadership, growth and cultures of respect with long-term success. Dr. DeWitt's pioneering work in drug discovery and development has led to four landmark M&A transactions in metabolic, cancer, and psychiatric disorders, demonstrating that lean, focused, and value-driven science can compete at the highest levels.

The details

Using the DECS R&D strategy, Dr. DeWitt and her team successfully developed and monetized three additional drug candidate portfolios in psychiatric disorders, cancer, and metabolic disorders through four M&A transactions between 2018 and 2025. Key scientific discoveries include identifying the preferred stereoisomers that drive efficacy in bupropion, avadomide, and pioglitazone.

  • In 2010, Dr. DeWitt invented Deuterium-Enabled Chiral Switching (DECS), a novel strategy to stabilize interconverting stereoisomers in racemic drugs.
  • Between 2012 and 2025, DeuteRx completed four M&A transactions for drug candidates in metabolic, cancer, and psychiatric disorders.
  • In 2025, Dr. DeWitt was inducted into the American Chemical Society (ACS) Medicinal Chemistry Hall of Fame and honored with the Kathryn C. Hach Award for Entrepreneurial Success and the Gertrude Elion Medicinal Chemistry Award.

The players

Sheila DeWitt, PhD

Chair, President, and CEO of DeuteRx, LLC, an industry-recognized life sciences executive and serial entrepreneur with more than 35 years of leadership in pharmaceutical and biotechnology companies.

DeuteRx, LLC

A privately held biopharmaceutical company dedicated to developing differentiated new medicines with improved therapeutic profiles for patients, pioneering the Deuterium-Enabled Chiral Switching (DECS) strategy to create differentiated new chemical entities.

Got photos? Submit your photos here. ›

What they’re saying

“Women's History Month is a time to reflect on the progress that has been made and the work that still lies ahead. I am proud of what the DeuteRx team has accomplished, not only with a commitment to advancing better medicines for patients, but in demonstrating that lean, focused, and value-driven science can compete at the highest levels. I hope our journey inspires and empowers the next generation of women in science, entrepreneurship, and leadership.”

— Sheila DeWitt, PhD, Chair, President & CEO, DeuteRx, LLC

What’s next

Building on its proven drug discovery track, the DeuteRx team is advancing programs in spasticity, neuropathic pain, and rare dermatologic conditions, continuing to apply the DECS strategy to create best-in-class therapeutics.

The takeaway

Dr. DeWitt's pioneering work in deuterium-enabled drug discovery has led to multiple successful M&A transactions, demonstrating that women-led, mission-driven science can thrive and make a significant impact in the pharmaceutical industry.